Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...

Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others.

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...

AstraZeneca’s Ultomiris shows promise in rare post-transplant complication There are currently no approved treatment options for HSCT-TMA AstraZeneca (AZ) has announced promising results from a ...

Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Ultomiris (ravulizumab) demonstrated clinically-meaningful overall survival at 26 weeks ...

Initiative’s growth came almost entirely from 11 existing pharma clients, including AstraZeneca, Bristol Myers Squibb, Merck and Gilead. It added work from Alexion Pharmaceuticals for Ultomiris.